Company Description
Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France.
It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.
The company provides Amphadase, an injection to absorb and disperse other injected drugs; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products; morphine injection for use with patient-controlled analgesia pumps; and Lorazepam injection for surgery and medical procedures.
In addition, it offers Neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; Isoproterenol hydrochloride injection for mild or transient episodes of heart block; Ganirelix Acetate injection for the inhibition of premature luteinizing hormone surges; Vasopressin to increase blood pressure; and Regadenoson, a stress agent for radionuclide myocardial perfusion imaging.
Further, the company distributes recombinant human insulin APIs and porcine insulin API. Additionally, it develops generic product candidates, such as injectable, inhalation, and analytical technologies; biosimial product candidates; and intranasal epinephrine for the treatment of allergic reactions.
The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.
| Country | United States |
| Founded | 1996 |
| IPO Date | Jun 25, 2014 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 1,761 |
| CEO | Dr. Yongfeng Zhang Ph.D. |
Contact Details
Address: 11570 Sixth Street Rancho Cucamonga, California 91730 United States | |
| Phone | 909-980-9484 |
| Website | amphastar.com |
Stock Details
| Ticker Symbol | AMPH |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001297184 |
| CUSIP Number | 03209R103 |
| ISIN Number | US03209R1032 |
| Employer ID | 33-0702205 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Ziping Luo Ph.D. | Chairman of the Board, Chief Scientist and Chief Operating Officer |
| Dr. Yongfeng Zhang Ph.D. | Co-Founder, President, Chief Executive Officer, Chief Scientific Officer and Director |
| William J. Peters M.B.A. | Chief Financial Officer, Executive Vice President of Finance, Treasurer and Director |
| Jacob Liawatidewi M.B.A. | Executive Vice President of Sales, Marketing and Corporate Administration Center, Corporate Secretary and Director |
| Rong Zhou M.S. | Senior Executive Vice President of Production |
| Dan Dischner M.B.A. | Vice President of Human Resources and Corporate Communication |
| Tony Marrs M.B.A., M.P.H. | Senior Vice President of Regulatory Affairs and Clinical Operations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 12, 2024 | ARS | Filing |
| Apr 12, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 12, 2024 | DEF 14A | Other definitive proxy statements |
| Apr 1, 2024 | 144 | Filing |
| Mar 6, 2024 | 144 | Filing |
| Mar 6, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Mar 5, 2024 | 144 | Filing |
| Mar 1, 2024 | 144 | Filing |
| Feb 29, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Feb 29, 2024 | 10-K | Annual Report |